Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

velpatasvir

- PMLiVE

FDA sets standard review for Gilead’s idelalisib in NHL

Comes despite accelerated review for drug’s use in chronic lymphocytic leukaemia

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Research Partnership

- PMLiVE

Boehringer’s faldaprevir set for rapid review in Europe

More competition in emerging hepatitis C market

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

Bristol-Myers Squibb (BMS) building

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

- PMLiVE

Merck stakes a claim to all-oral hepatitis C market

Positive data for interferon-free regimen

- PMLiVE

Incivek decline forces Vertex job cuts

370 positions to be axed

- PMLiVE

Gilead’s sofosbuvir aces FDA advisory committee

On track for hepatitis C approval in US

- PMLiVE

J&J wins FDA panel backing for hepatitis C drug

Simeprevir would challenge Victrelis and Incivek if approved

- PMLiVE

Gilead halts leukaemia study on positive results

Idelalisib provides significant benefit in chronic lymphocytic leukaemia

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

GSK’s Revolade cleared for use in hepatitis C therapy

Adds to drug’s existing thrombocytopenia indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links